The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset

David Safronetz, Kyle Rosenke, Jonna B. Westover, Cynthia Martellaro, Atsushi Okumura, Yousuke Furuta, Joan Geisbert, Greg Saturday, Takashi Komeno, Thomas Geisbert, Heinz Feldmann, Brian B. Gowen

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

With up to 500,000 infections annually, Lassa virus (LASV), the cause of Lassa fever, is one of the most prevalent etiological agents of viral hemorrhagic fever (VHF) in humans. LASV is endemic in several West African countries with sporadic cases and prolonged outbreaks observed most commonly in Sierra Leone, Liberia, Guinea and Nigeria. Additionally several cases of Lassa fever have been imported into North America, Europe and Asia making LASV a global threat to public health. Despite this, currently no approved therapeutic or vaccine exists to treat or prevent LASV infections. Here, using a passaged strain of LASV that is uniformly lethal in Hartley Guinea pigs, we demonstrate that favipiravir, a broad-spectrum antiviral agent and leading treatment option for influenza, has potent activity against LASV infection. In this model, once daily treatment with favipiravir significantly reduced viral titers in tissue samples and reduced mortality rates when compared with animals receiving vehicle-only or ribavirin, the current standard of care for Lassa fever. Favipiravir remained highly effective against lethal LASV infection when treatments were initiated nine days post-infection, a time when animals were demonstrating advanced signs of disease. These results support the further preclinical evaluation of favipiravir for Lassa fever and other VHFs.

Original languageEnglish (US)
Article number14775
JournalScientific Reports
Volume5
DOIs
StatePublished - Oct 12 2015

Fingerprint

Lassa virus
Virus Diseases
Lassa Fever
Antiviral Agents
Guinea Pigs
Viral Hemorrhagic Fevers
Liberia
Northern Asia
Sierra Leone
Guinea
Ribavirin
Standard of Care
Nigeria
North America
Infection
favipiravir
Human Influenza
Disease Outbreaks
Vaccines
Public Health

ASJC Scopus subject areas

  • General

Cite this

Safronetz, D., Rosenke, K., Westover, J. B., Martellaro, C., Okumura, A., Furuta, Y., ... Gowen, B. B. (2015). The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset. Scientific Reports, 5, [14775]. https://doi.org/10.1038/srep14775

The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset. / Safronetz, David; Rosenke, Kyle; Westover, Jonna B.; Martellaro, Cynthia; Okumura, Atsushi; Furuta, Yousuke; Geisbert, Joan; Saturday, Greg; Komeno, Takashi; Geisbert, Thomas; Feldmann, Heinz; Gowen, Brian B.

In: Scientific Reports, Vol. 5, 14775, 12.10.2015.

Research output: Contribution to journalArticle

Safronetz, D, Rosenke, K, Westover, JB, Martellaro, C, Okumura, A, Furuta, Y, Geisbert, J, Saturday, G, Komeno, T, Geisbert, T, Feldmann, H & Gowen, BB 2015, 'The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset', Scientific Reports, vol. 5, 14775. https://doi.org/10.1038/srep14775
Safronetz, David ; Rosenke, Kyle ; Westover, Jonna B. ; Martellaro, Cynthia ; Okumura, Atsushi ; Furuta, Yousuke ; Geisbert, Joan ; Saturday, Greg ; Komeno, Takashi ; Geisbert, Thomas ; Feldmann, Heinz ; Gowen, Brian B. / The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset. In: Scientific Reports. 2015 ; Vol. 5.
@article{29e490fb584b4a2fb7f0a55ec33175c5,
title = "The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset",
abstract = "With up to 500,000 infections annually, Lassa virus (LASV), the cause of Lassa fever, is one of the most prevalent etiological agents of viral hemorrhagic fever (VHF) in humans. LASV is endemic in several West African countries with sporadic cases and prolonged outbreaks observed most commonly in Sierra Leone, Liberia, Guinea and Nigeria. Additionally several cases of Lassa fever have been imported into North America, Europe and Asia making LASV a global threat to public health. Despite this, currently no approved therapeutic or vaccine exists to treat or prevent LASV infections. Here, using a passaged strain of LASV that is uniformly lethal in Hartley Guinea pigs, we demonstrate that favipiravir, a broad-spectrum antiviral agent and leading treatment option for influenza, has potent activity against LASV infection. In this model, once daily treatment with favipiravir significantly reduced viral titers in tissue samples and reduced mortality rates when compared with animals receiving vehicle-only or ribavirin, the current standard of care for Lassa fever. Favipiravir remained highly effective against lethal LASV infection when treatments were initiated nine days post-infection, a time when animals were demonstrating advanced signs of disease. These results support the further preclinical evaluation of favipiravir for Lassa fever and other VHFs.",
author = "David Safronetz and Kyle Rosenke and Westover, {Jonna B.} and Cynthia Martellaro and Atsushi Okumura and Yousuke Furuta and Joan Geisbert and Greg Saturday and Takashi Komeno and Thomas Geisbert and Heinz Feldmann and Gowen, {Brian B.}",
year = "2015",
month = "10",
day = "12",
doi = "10.1038/srep14775",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset

AU - Safronetz, David

AU - Rosenke, Kyle

AU - Westover, Jonna B.

AU - Martellaro, Cynthia

AU - Okumura, Atsushi

AU - Furuta, Yousuke

AU - Geisbert, Joan

AU - Saturday, Greg

AU - Komeno, Takashi

AU - Geisbert, Thomas

AU - Feldmann, Heinz

AU - Gowen, Brian B.

PY - 2015/10/12

Y1 - 2015/10/12

N2 - With up to 500,000 infections annually, Lassa virus (LASV), the cause of Lassa fever, is one of the most prevalent etiological agents of viral hemorrhagic fever (VHF) in humans. LASV is endemic in several West African countries with sporadic cases and prolonged outbreaks observed most commonly in Sierra Leone, Liberia, Guinea and Nigeria. Additionally several cases of Lassa fever have been imported into North America, Europe and Asia making LASV a global threat to public health. Despite this, currently no approved therapeutic or vaccine exists to treat or prevent LASV infections. Here, using a passaged strain of LASV that is uniformly lethal in Hartley Guinea pigs, we demonstrate that favipiravir, a broad-spectrum antiviral agent and leading treatment option for influenza, has potent activity against LASV infection. In this model, once daily treatment with favipiravir significantly reduced viral titers in tissue samples and reduced mortality rates when compared with animals receiving vehicle-only or ribavirin, the current standard of care for Lassa fever. Favipiravir remained highly effective against lethal LASV infection when treatments were initiated nine days post-infection, a time when animals were demonstrating advanced signs of disease. These results support the further preclinical evaluation of favipiravir for Lassa fever and other VHFs.

AB - With up to 500,000 infections annually, Lassa virus (LASV), the cause of Lassa fever, is one of the most prevalent etiological agents of viral hemorrhagic fever (VHF) in humans. LASV is endemic in several West African countries with sporadic cases and prolonged outbreaks observed most commonly in Sierra Leone, Liberia, Guinea and Nigeria. Additionally several cases of Lassa fever have been imported into North America, Europe and Asia making LASV a global threat to public health. Despite this, currently no approved therapeutic or vaccine exists to treat or prevent LASV infections. Here, using a passaged strain of LASV that is uniformly lethal in Hartley Guinea pigs, we demonstrate that favipiravir, a broad-spectrum antiviral agent and leading treatment option for influenza, has potent activity against LASV infection. In this model, once daily treatment with favipiravir significantly reduced viral titers in tissue samples and reduced mortality rates when compared with animals receiving vehicle-only or ribavirin, the current standard of care for Lassa fever. Favipiravir remained highly effective against lethal LASV infection when treatments were initiated nine days post-infection, a time when animals were demonstrating advanced signs of disease. These results support the further preclinical evaluation of favipiravir for Lassa fever and other VHFs.

UR - http://www.scopus.com/inward/record.url?scp=84943800811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943800811&partnerID=8YFLogxK

U2 - 10.1038/srep14775

DO - 10.1038/srep14775

M3 - Article

C2 - 26456301

AN - SCOPUS:84943800811

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 14775

ER -